Insights

Home » Insights » Insights Intercept Blood System
Cerus 22/07/2019

ISBT Basel 2019 - Presentations

PresentationsCerus Satellite Symposium at ISBT Basel 2019

"Safeguarding the blood supply against (re)emerging pathogens. Balancing blood safety and economics"

Have you had the opportunity to join Cerus Satellite symposium on Tuesday June 25, 2019 at the ISBT in Basel? Regardless, we are pleased to share the presentations with you from the Cerus Symposium. 

Cerus 08/08/2018

Madrid adopts INTERCEPT™

On October 30, 2017 Cerus Corp. announced that it has entered into a two-year supply contract with Centro de Transfusion de la Comunidad de Madrid (CTCM) for the INTERCEPT Blood System for platelets.

Cerus 08/08/2018

EFS adopts INTERCEPT

The French Ministry of Health decided late 2016 that platelet pathogen inactivation should be deployed throughout the entire French territory for the control of bacterial infections transmitted by transfusion, following the recommendations of the National Agency for the Safety of Medicines and Health Products (ANSM).

Cerus 06/08/2018

Let us do something about it!

In 1982 was an epidemic of HIV in San Francisco. 300 patients acquired HIV infections from blood transfusions. The patients did not blame the hospital, but simply asked “Do something about it”. This request became the personal motivation of M.D. Larry Corash to found Cerus.

Cerus 06/07/2018

2 million Swiss francs to develop a whole blood PI system in Africa

The Swiss Red Cross Humanitarian Foundation has awarded a grant of 2 million Swiss Francs to Cerus, the University Hospital of Basel, and the Swiss Transfusion SRC to complete the necessary clinical studies to develop a whole blood pathogen inactivation system for use in Africa. 

Cerus 06/07/2018

$180 million to support  development of Cerus' RBC programme

Cerus has entered an agreement with the Biomedical Advanced Research and Development Authority (BARDA) to support Cerus’ clinical development program for pathogen reduction of red blood cell (RBC) components, including access to funding that could support various activities, such as the funding of studies necessary to support an FDA submission and to accelerate commercial scale.